STUDY QUESTION: What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise and consumer preference?
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive aged women, with a prevalence of between 8 and 13% depending on the population studied and definitions used (Teede et al., 2010; Azziz et al., 2016) . PCOS is complex with reproductive, metabolic and psychological features (Teede et al., 2010; Azziz et al., 2016) . Clinical practice in the assessment and management of PCOS is inconsistent, with key evidence practice gaps, whilst women internationally have highlighted delayed diagnosis and dissatisfaction with care (Teede et al., 2014; Dokras et al., 2017; . Current guidelines either are limited in breadth, do not follow rigorous best practice in development, have not involved consumers, or are outdated (Teede et al., 2011; Legro et al., 2013; Conway et al., 2014; Goodman et al., 2015; Balen et al., 2016) , resulting in inconsistent guidance for clinicians and women alike. To address these identified gaps, here we summarize the development process and recommendations from the first international evidence-based guideline for the assessment and management of PCOS, bringing together extensive consumer engagement and international collaboration with leading societies and organizations, multidisciplinary experts, and primary care representatives. In this process, the guideline development groups (GDG) unanimously supported the Rotterdam diagnostic criteria (Group, 2004) for adult women. This comprehensive evidence-based guideline builds on prior highquality guidelines and culminates from a rigorous, Appraisal of Guidelines for Research and Evaluation-II (AGREE-II)-compliant, evidence-based guideline development process. It provides a single source of international evidence-based recommendations (EBR) to guide clinical practice with the opportunity for adaptation in relevant health systems. Together with an extensive translation program, the aim is to reduce worldwide variation in care and promote high-quality service provision to improve health outcomes and quality of life in women with PCOS. The guidelines are supported by a multifaceted international translation program with co-designed resources to enhance the skills of health professionals and empower women with PCOS, with an integrated comprehensive evaluation program.
What Does This Mean for Adolescents and Women With PCOS?
This guideline aims to optimize the evidence-based, consistent care that meets the needs and improves the quality of life of women with PCOS. The guideline and translation program were developed with full consumer participation at all stages, targeting areas and outcomes of priority for women with PCOS. The aim is to support women and their healthcare providers to optimize diagnosis, assessment and management of PCOS. There is an emphasis on partnership in care and empowerment of women with PCOS. Personal characteristics, preferences, culture and values are considered. With effective translation, the guideline and health professional and consumer resources will address gaps and priorities identified by women with PCOS and will promote vital future research.
Materials and Methods
Best practice evidence-based guideline development methods were applied and are detailed in the full guideline and the technical reports and outlined in Figure 1 and available at https://www.monash.edu/medicine/ sphpm/mchri/pcos (Misso and Teede, 2012) . The process aligns with all elements of the AGREE-II tool for quality guideline assessment (Brouwers et al., 2010) . This involved extensive evidence synthesis and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework covering evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength (GRADE working group). Evidence synthesis methods are outlined in the full guideline and followed best practice (NHMRC, 2007 (NHMRC, , 2009 Brouwers et al., 2010; GRADE working group) . Categories include evidence-based or consensus recommendations with accompanying clinical practice points (Table I) .
Terms include 'should', 'could' and 'should not' are informed by the nature of the recommendation (evidence or consensus), the GRADE framework, and quality of the evidence and are independent descriptors reflecting the judgment of the multidisciplinary GDG, including consumers. They refer to overall interpretation and practical application of the recommendation, balancing benefits and harms. 'Should' is used where benefits of the recommendation exceed harms, and where the recommendation can be trusted to guide practice. 'Could' is used where either the quality of evidence was limited or the available studies demonstrate little clear advantage of one approach over another, or the balance of benefits to harm was unclear. 'Should not' is used where there is either a lack of appropriate evidence, or the harms may outweigh the benefits.
The GRADE of the recommendation is determined by the GDG based on comprehensive structured consideration of all elements of the GRADE framework (GRADE working group), including desirable effects, undesirable effects, balance of effects, resource requirements and cost effectiveness, equity, acceptability and feasibility, and includes: *Conditional recommendation against the option; **conditional recommendation for either the option or the comparison; ***conditional recommendation for the option; and ****strong recommendation for the option.
Quality of the evidence is categorized according to the number and design of studies addressing the outcome; judgments about the quality of the studies and/or synthesized evidence, such as risk of bias, inconsistency, indirectness, imprecision and any other considerations that may influence the quality of the evidence; key statistical data; and classification of the importance of the outcomes (Table II ). The quality of evidence reflects the extent of confidence in an estimate of the effect to support a particular recommendation (GRADE working group) and was largely determined by the expert evidence synthesis team.
GRADE acknowledges that evidence quality is a continuum; any discrete categorization involves a degree of arbitrariness. Nevertheless, the advantages of simplicity, transparency and clarity outweigh these limitations (GRADE working group).
Results
The recommendation table (Table III) applies the category, descriptive terms, GRADE of the recommendations and the quality of the evidence. The full guideline is available at https://www.monash.edu/ medicine/sphpm/mchri/pcos. The full version of the guideline outlines the clinical need for the question, the clinical question, the Figure 1 The steps in developing an evidence-based guideline. GDG = guideline development group; PICO = P: patient, problem or population, I: intervention, C: comparison, control or comparator, O: outcome. Reprinted with permissions from Misso and Teede (2012) . evidence summary, the recommendation and practice points, and a summary of the justification developed by the GDGs using the GRADE framework, refined by extensive international peer review. The comprehensive evidence reviews, profiles and GRADE frameworks supporting each recommendation, can be found at https:// www.monash.edu/medicine/sphpm/mchri/pcos in the Supplementary Technical Reports. The peer review feedback, administrative report on guideline development and disclosure of interest process and declarations can be found at https://www.monash.edu/medicine/sphpm/ mchri/pcos. Here we present the clinical topic area recommendations and practice points (Table III) . This summary, the full guideline and technical reports are supported by a comprehensive co-designed translation program to optimize dissemination and impact with resources freely available at https://www.monash.edu/medicine/sphpm/mchri/pcos.
Discussion
The International Guideline for the Assessment and Management of PCOS and the related translation program aims to provide clinicians with a quality, reliable source of international EBR to guide consistent clinical practice and to empower women with evidence-based information. All recommendations were formulated after an assessment of the best available evidence, multidisciplinary clinical expertise, consumer preferences and structured review by the five GDGs. Detailed methods for stakeholder engagement and guideline development can be found at https://www.monash.edu/medicine/sphpm/mchri/ pcos. The guideline provides 166 recommendations: EBR = 31, clinical consensus recommendations (CCR) = 59, and clinical practice points (CPP) = 76. Overall, evidence is of low to moderate quality, requiring significant research expansion in this neglected, yet common condition.
We endorse the Rotterdam PCOS Diagnostic Criteria in adults (two of oligo-or anovulation, clinical and/or biochemical hyperandrogenism, or polycystic ovaries on ultrasound), after exclusion of related disorders. Where both oligo-or anovulation and hyperandrogenism are present, ultrasound is not necessary for diagnosis. In adolescents, both oligo-anovulation and hyperandrogenism are required, with ultrasound not recommended for diagnosis. Ultrasound criteria are refined with advancing technology. Anti-Müllerian hormone levels are not yet adequate for diagnosis of PCOS. Insulin resistance is recognized as a key feature of PCOS, yet clinical measurement is not recommended at the current time. Once diagnosed, assessment and management includes reproductive, metabolic, and psychological features. Education, self-empowerment, multidisciplinary care and lifestyle intervention for prevention or management of excess weight are prioritized. Depressive and anxiety symptoms should be screened, assessed and managed, and health professionals should be aware of other impacts on emotional wellbeing and quality of life. Combined oral contraceptive pills are first-line pharmacological management for menstrual irregularity and hyperandrogenism, with no specific formulation recommended and with low-dose preparations preferred. Metformin is recommended in addition or alone, primarily for management of metabolic features. Letrozole is first-line pharmacological infertility therapy; with clomiphene and metformin both having a role, alone and in combination. In women with PCOS and anovulatory infertility, gonadotrophins are second line. In the absence of an absolute indication for IVF, women with PCOS and anovulatory infertility could be offered IVF third line where other ovulation induction therapies have failed.
The combined effects of the provision of a single source of evidence-based recommendations and a comprehensive international translation and dissemination program will amplify the impact of the guideline and recommendations globally. It will support and build the capability of health professionals to deliver high-quality, evidencebased assessment and management of PCOS and will augment the health literacy and self-management of PCOS health consumers. The guideline recommendations are protected under copyright, however the process for adaption of guideline recommendations to the regional context is available at https://www.monash.edu/medicine/sphpm/ mchri/pcos. The guideline and translation program will contribute to early diagnosis and improved health outcomes, and promote bestpractice PCOS models of care. The translation program will be inclusive of a range of outputs such as the first evidence-based PCOS APP (AskPCOS), a rigorously developed question prompt list to optimize health professional engagement, health literacy enhancing tools, comprehensive PCOS-related health information; internationally accessible health professional accredited courses, webinars with international expert panels, and e-health information resources available at https:// www.monash.edu/medicine/sphpm/mchri/pcos. Most importantly, the guideline and translation of the guideline is expected to improve CPP Reliable assessment of biochemical hyperandrogenism is not possible in women on hormonal contraception, due to effects on sex hormone-binding globulin and altered gonadotrophin-dependent androgen production.
_ CPP Where assessment of biochemical hyperandrogenism is important in women on hormonal contraception, drug withdrawal is recommended for months or longer before measurement, and contraception management with a non-hormonal alternative is needed during this time.
_ CPP Assessment of biochemical hyperandrogenism is most useful in establishing the diagnosis of PCOS and/or phenotype where clinical signs of hyperandrogenism (in particular hirsutism) are unclear or absent.
_ CPP Interpretation of androgen levels needs to be guided by the reference ranges of the laboratory used, acknowledging that ranges for different methods and laboratories vary widely. Normal values are ideally based on levels from a well phenotyped healthy control population or by cluster analysis of a large general population considering age and pubertal specific stages.
_ CPP Where androgen levels are markedly above laboratory reference ranges, other causes of biochemical hyperandrogenism need to be considered. History of symptom onset and progression is critical in assessing for neoplasia, however, some androgen-secreting neoplasms may only induce mild to moderate increases in biochemical hyperandrogenism.
_

Clinical hyperandrogenism
CCR A comprehensive history and physical examination should be completed for symptoms and signs of clinical hyperandrogenism, including acne, alopecia, and hirsutism and, in adolescents, severe acne and hirsutism. 
Table III Continued
Category (see Table I for definition)
Recommendation GRADE and quality
CCR
The Ludwig visual score is preferred for assessing the degree and distribution of alopecia. **** CPP There are no universally accepted visual assessments for evaluating acne.
CPP
The prevalence of hirsutism is the same across ethnicities, yet the mFG cut-off scores for defining hirsutism and the severity of hirsutism varies by ethnicity.
_ CPP As ethnic variation in vellus hair density is notable, over-estimation of hirsutism may occur if vellus hair is confused with terminal hair; only terminal hairs need to be considered in pathological hirsutism, with terminal hairs clinically growing >5 mm in length if untreated, varying in shape and texture and generally being pigmented.
_
Ultrasound and polycystic ovarian morphology (PCOM)
CCR Ultrasound should not be used for the diagnosis of PCOS in those with a gynecological age of <8 years (<8 years after menarche), due to the high incidence of multi-follicular ovaries in this life stage.
**** CCR The threshold for PCOM should be revised regularly with advancing ultrasound technology, and age-specific cut off values for PCOM should be defined.
**** CCR The transvaginal ultrasound approach is preferred in the diagnosis of PCOS, if sexually active and if acceptable to the individual being assessed.
**** CCR Using endovaginal ultrasound transducers with a frequency bandwidth that includes 8 MHz, the threshold for PCOM on either ovary, a follicle number per ovary of ≥20 and/or an ovarian volume ≥10 ml on either ovary, ensuring no corpora lutea, cysts or dominant follicles are present.
*** CPP If using older technology, the threshold for PCOM could be an ovarian volume ≥10 ml on either ovary. _ CPP In patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not necessary for PCOS diagnosis; however, ultrasound will identify the complete PCOS phenotype.
_ CPP
In transabdominal ultrasound reporting is best focused on ovarian volume with a threshold of ≥10 ml, given the difficulty of reliably assessing follicle number with this approach. **** CPP To achieve weight loss in those with excess weight, an energy deficit of 30% or 500-750 kcal/day (1200-1500 kcal/day) could be prescribed for women, also considering individual energy requirements, body weight and physical activity levels.
_ CPP In women with PCOS, there is no or limited evidence that any specific energy equivalent diet type is better than another, or that there is any differential response to weight management intervention, compared to women without PCOS.
_ CPP Tailoring of dietary changes to food preferences, allowing for a flexible and individual approach to reducing energy intake and avoiding unduly restrictive and nutritionally unbalanced diets, are important, as per general population recommendations.
_
Exercise intervention CCR Health professionals should encourage and advise the following for prevention of weight gain and maintenance of health:
• In adults from 18-64 years, a minimum of 150 min/week of moderate intensity physical activity or 75 min/ week of vigorous intensities or an equivalent combination of both, including muscle strengthening activities on 2 non-consecutive days/week • In adolescents, at least 60 min of moderate to vigorous intensity physical activity/day, including those that strengthen muscle and bone at least 3 times weekly • Activity be performed in at least 10-min bouts or around 1000 steps, aiming to achieve at least 30 min daily on most days. *** CCR Health professionals should encourage and advise the following for modest weight-loss, prevention of weightregain and greater health benefits:
• A minimum of 250 min/week of moderate intensity activities or 150 min/week of vigorous intensity or an equivalent combination of both, and muscle strengthening activities involving major muscle groups on 2 nonconsecutive days/week. 
Table III Continued
Recommendation GRADE and quality CPP Prevention of weight gain, monitoring of weight and encouraging evidence-based and socio-culturally appropriate healthy lifestyle is important in PCOS, particularly from adolescence. • The lowest effective estrogen doses (such as 20-30 µg of ethinyloestradiol or equivalent), and natural estrogen preparations are preferred, balancing efficacy, metabolic risk profile, side effects, cost and availability.
• The generally limited evidence on effects of COCPs in PCOS needs to be appreciated with practice informed by general population guidelines (World Health Organization Guidelines).
• The relative and absolute contraindications and side effects of COCPs need to be considered and be the subject of individualized discussion.
• PCOS specific risk factors such as high BMI, hyperlipidemia and hypertension need to be considered.
_
Combined oral contraceptive pills in combination with metformin and/or anti-androgen pharmacological agents
EBR
In combination with the COCP, metformin should be considered in women with PCOS for management of metabolic features where COCP and lifestyle changes do not achieve desired goals. **** ⊕⊕○○ EBR In combination with the COCP, metformin could be considered in adolescents with PCOS and BMI ≥ 25 kg/ m 2 where COCP and lifestyle changes do not achieve desired goals. **** ⊕⊕○○
CPP
In combination with the COCP, metformin may be most beneficial in high metabolic risk groups including those with diabetes risk factors, impaired glucose tolerance or high-risk ethnic groups.
_ EBR
In combination with the COCP, antiandrogens should only be considered in PCOS to treat hirsutism, after 6 months or more of COCP and cosmetic therapy have failed to adequately improve symptoms.
** ⊕⊕○○
CCR
In combination with the COCP, antiandrogens could be considered for the treatment of androgen-related alopecia in PCOS.
** CPP In PCOS, antiandrogens must be used with effective contraception, to avoid male fetal undervirilisation. Variable availability and regulatory status of these agents is notable and for some agents, potential liver toxicity requires caution. _ CPP Where metformin is prescribed the following need to be considered:
• Adverse effects, including gastrointestinal side-effects that are generally dose dependent and self-limiting, need to be the subject of individualized discussion.
• Starting at a low dose, with 500 mg increments 1-2 weekly and extended release preparations may minimize side effects.
• Metformin use appears safe long term, based on use in other populations, however, ongoing requirement needs to be considered and use may be associated with low vitamin B12 levels.
• Use is generally off label and health professionals need to inform women and discuss the evidence, possible concerns and side effects. • Cost and availability.
• Expertise required for use in ovulation induction.
• Degree of intensive ultrasound monitoring required.
• Lack of difference in clinical efficacy of available gonadotrophin preparations.
• Low dose gonadotrophin protocols optimize monofollicular development.
• Risk and implications of potential multiple pregnancy.
_ CPP Gonadotrophin induced ovulation is only triggered when there are fewer than three mature follicles and needs to be canceled if there are more than two mature follicles with the patient advised to avoid unprotected intercourse.
_ Anti-obesity pharmacological agents CCR Pharmacological anti-obesity agents should be considered an experimental therapy in women with PCOS for the purpose of improving fertility, with risk to benefit ratios currently too uncertain to advocate this as fertility therapy. Table I for definition)
Recommendation GRADE and quality CPP Risks need to be explained to all women with PCOS considering laparoscopic ovarian surgery. _ CPP Where laparoscopic ovarian surgery is to be recommended, the following need to be considered:
• Comparative cost.
• Intra-operative and post-operative risks are higher in women who are overweight and obese.
• There may be a small associated risk of lower ovarian reserve or loss of ovarian function.
• Periadnexal adhesion formation may be an associated risk.
_
Bariatric surgery CCR Bariatric surgery should be considered an experimental therapy in women with PCOS, for the purpose of having a healthy baby, with risk to benefit ratios currently too uncertain to advocate this as fertility therapy.
* CPP If bariatric surgery is to be prescribed, the following need to be considered:
• The need for a structured weight management program involving diet, physical activity and interventions to improve psychological, musculoskeletal and cardiovascular health to continue post-operatively.
• Perinatal risks such as small for gestational age, premature delivery, possibly increased infant mortality.
• Potential benefits such as reduced incidence of large for gestational age fetus and gestational diabetes.
• Recommendations for pregnancy avoidance during periods of rapid weight loss and for at least 12 months after bariatric surgery with appropriate contraception. If pregnancy occurs, the following need to be considered:
• Awareness and preventative management of pre-and post-operative nutritional deficiencies is important, ideally in a specialist interdisciplinary care setting.
• Monitoring of fetal growth during pregnancy.
In vitro fertilization (IVF)
CCR
In the absence of an absolute indication for IVF ± ICSI), women with PCOS and anovulatory infertility could be offered IVF as third line therapy where first or second line ovulation induction therapies have failed.
*** CPP In women with anovulatory PCOS, the use of IVF is effective and when elective single embryo transfer is used, multiple pregnancies can be minimized.
_ CPP Women with PCOS undergoing IVF ± ICSI therapy need to be counseled prior to starting treatment including on:
• Availability, cost and convenience.
• Increased risk of ovarian hyperstimulation syndrome.
• Options to reduce the risk of ovarian hyperstimulation. _ CCR Urinary or recombinant follicle stimulation hormone can be used in women with PCOS undergoing controlled ovarian hyperstimulation for IVF ± ICSI, with insufficient evidence to recommend specific follicle stimulating hormone (FSH) preparations.
_ CCR
Exogenous recombinant luteinizing hormone treatment should not be routinely used in combination with follicle stimulating hormone therapy in women with PCOS undergoing controlled ovarian hyperstimulation for IVF ± ICSI. _ EBR A gonadotrophin releasing hormone antagonist protocol is preferred in women with PCOS undergoing an IVF ± ICSI cycle, over a gonadotrophin releasing hormone agonist long protocol, to reduce the duration of stimulation, total gonadotrophin dose and incidence of ovarian hyperstimulation syndrome (OHSS). *** ⊕⊕○○ CPP Human chorionic gonadotrophin is best used at the lowest doses to trigger final oocyte maturation in women with PCOS undergoing an IVF ± ICSI cycle to reduce the incidence of OHSS.
_ CPP Triggering final oocyte maturation with a gonadotropin-releasing hormone (GnRH) agonist and freezing all suitable embryos could be considered in women with PCOS having an IVF/ICSI cycle with a GnRH antagonist protocol and at an increased risk of developing OHSS or where fresh embryo transfer is not planned.
_ CPP In IVF ± ICSI cycles in women with PCOS, consideration needs to be given to an elective freeze of all embryos. _ EBR Adjunct metformin therapy could be used before and/or during follicle stimulating hormone ovarian stimulation in women with PCOS undergoing a IVF ± ICSI therapy with a GnRH agonist protocol, to improve the clinical pregnancy rate and reduce the risk of OHSS.
*** ⊕⊕○○
CCR
In a GnRH agonist protocol with adjunct metformin therapy, in women with PCOS undergoing IVF ± ICSI treatment, the following could be considered:
• Metformin commencement at the start of GnRH agonist treatment.
• Metformin use at a dose of between 1000 and 2550 mg daily.
• Metformin cessation at the time of the pregnancy test or menses (unless the metformin therapy is otherwise indicated).
• Metformin side-effects (see metformin section in this table).
_
Continued patient experiences through the provision of timely and accurate diagnosis, accessible evidence-based information and improved multidisciplinary support. Ultimately, this initiative may serve as an exemplar for international collaborative engagement and healthcare impact. Key elements included extensive collaboration, broad stakeholder representation, including consumer partnership, distributive leadership, adequate funding, robust project management and governance, adherence to best practice and integrated comprehensive translation and evaluation. chairing the GDG process and GRADE framework application, finalizing recommendations, responding to feedback and endorsing the guideline. Helena Teede was the guideline development and translation lead and engaged with all GDG meetings, overseeing the process. Joop Laven, Anuja Dokras, Lisa Moran, Terhi Piltonen and Michael Costello chaired the GDGs. Marie Misso led the guideline development and evidence synthesis processes. Robert Norman was the PCOS Centre for Research Excellence co-director, the deputy chair of the International advisory board and the deputy chair of two GDG's. All other authors, were actively engaged as guideline development group, consumer, translation or international advisory board members or members of the evidence synthesis and translation team, contributed to the article, prioritizing clinical questions, discussing recommendations until voting and consensus, responses to external peer review and approval of the final recommendations across all GDGs.
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